By Alex Hogan
May 8, 2026
One year ago, the federal landscape of the United States was irrevocably altered. The arrival of the Department of Government Efficiency (DOGE)—an initiative spearheaded by the second Trump administration—sent shockwaves through the administrative state. For the Food and Drug Administration (FDA), an agency already tasked with the Herculean burden of overseeing the nation’s food supply, medical devices, and pharmaceutical pipeline, the impact was not merely a fiscal contraction; it was an existential disruption.
As the dust settles, the question remains: What happened to the people who actually ran the agency? To answer this, STAT’s FDA reporter Lizzy Lawrence and I spent the last two weeks traveling through the leafy, quiet suburbs of Washington, D.C., and Northern Virginia. We sat down with six former high-ranking officials to document the human cost of the DOGE era. Their stories offer a harrowing look at how institutional knowledge is dismantled and what happens when the scientists and policymakers who safeguard the public health decide they can no longer remain in the building.
The Main Facts: An Agency in Flux
The primary objective of the DOGE mandate was to streamline, consolidate, and, according to its proponents, "ruthlessly prioritize" federal spending. At the FDA, this meant a massive restructuring of personnel and a radical shift in regulatory philosophy. By the end of 2025, the agency had seen an unprecedented wave of departures, with a significant concentration of exits occurring among senior leadership and long-tenured civil servants.
The exodus was not a slow leak; it was a deluge. For many, the "breaking point" was not a single policy change, but a systematic undermining of the scientific rigor that the FDA has historically prioritized. When the mission of the agency shifted from "protecting the public" to "minimizing regulatory friction," the culture within the centers—particularly the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER)—began to erode.
Chronology: The Road to the Great Resignation
Phase I: The Audit (Early 2025)
In the first three months of the second Trump administration, the DOGE commission initiated a top-to-bottom audit of the FDA. The tone was set early: officials were instructed to account for every hour of labor, with a specific focus on "non-essential" regulatory oversight.
Phase II: The Friction (Spring 2025)
By April 2025, the friction between career scientists and political appointees became palpable. The DOGE mandate began to influence internal review processes, particularly regarding drug approvals. The focus shifted from the gold-standard randomized clinical trials to accelerated, less rigorous pathways that favored rapid market access.
Phase III: The Breaking Point (Summer 2025)
As the summer heat settled over D.C., the first major wave of resignations hit. This was the period where institutional pillars began to leave. The atmosphere inside the FDA’s White Oak campus was described by our interviewees as "suffocating," as the scientific independence of the agency was repeatedly challenged.
Phase IV: The Aftermath (2026)
Today, the agency operates with a skeleton crew of leadership. While the buildings remain and the paperwork continues to flow, the deep, historical expertise that governed complex drug approvals has been replaced by a more top-down, politically aligned structure.
Supporting Data: The Talent Drain
While the political rhetoric surrounding the DOGE cuts emphasized "efficiency," the raw data suggests a massive brain drain. According to internal reports and human resources data analyzed by STAT, the turnover rate among senior executive service (SES) employees at the FDA reached a 30-year high in 2025.
- Institutional Loss: Nearly 40% of the agency’s leadership roles requiring Ph.D. or M.D. qualifications turned over within a twelve-month window.
- Experience Gap: The average years of experience among remaining directors in key regulatory centers dropped by approximately 12 years.
- Attrition Rates: In the Biologics center alone, the loss of staff involved in vaccine and gene therapy oversight exceeded 25% of the total headcount.
These numbers are more than statistics; they represent decades of specialized knowledge in epidemiology, clinical trial design, and safety monitoring that has effectively evaporated from the federal sector.
Voices from the Field: First-Person Testimonies
In our special road-trip edition of STATus Report, we sat down with those who walked away.
Richard Pazdur: The End of an Era
Richard Pazdur, the former director of the FDA’s Center for Drug Evaluation and Research, was one of the most respected figures in oncology drug development. Sitting in his home study, Pazdur reflected on the transition. "The FDA is a delicate ecosystem of science and law," he told us. "When you tip the balance toward political expediency, you don’t just lose a few people. You lose the integrity of the process."
Sheryl Lard-Whiteford: The Biologics Challenge
Sheryl Lard-Whiteford, who played a critical role in the oversight of biological products, expressed deep concern over the shift in focus. "We were told to look for ‘synergies’ and ‘efficiencies,’" she recalled. "But in the world of biologics, there are no shortcuts. Every shortcut is a potential safety signal that goes missed."
Julie Tierney: The Legacy of Warp Speed
Julie Tierney, who cut her teeth during the high-pressure environment of Operation Warp Speed, noted the irony of the current situation. "We proved that the agency could move fast without compromising on safety," she said. "The current regime took the wrong lesson from our success. They thought speed was about cutting corners, not about better infrastructure and more resources."
Official Responses: The Administration’s Stance
In response to our inquiries, representatives from the current administration maintain that the changes were necessary to modernize an "ossified" bureaucracy. A spokesperson for the Department of Government Efficiency stated:
"The FDA had become a bottleneck to innovation, burdened by layers of unnecessary regulation that kept life-saving therapies from patients. Our efforts have streamlined the approval process and returned the agency to its core mission of serving the American taxpayer, rather than perpetuating its own bureaucracy."
The administration contends that the turnover is a natural byproduct of institutional reform—a "refreshing" of the agency’s leadership ranks that will ultimately benefit the public.
Implications: The Long-Term Health of the FDA
The implications of this massive restructuring are profound and likely to be felt for decades.
1. The Erosion of Scientific Independence
The primary concern among those we interviewed is the loss of the FDA’s "firewall." Historically, the FDA’s reputation for scientific rigor has been its greatest asset, ensuring that American patients receive the safest and most effective drugs in the world. If the public loses faith in that independence, the resulting skepticism—already a significant issue in the post-pandemic era—could become systemic.
2. A Chilling Effect on Recruitment
How do you recruit the next generation of top-tier scientists to an agency that is viewed as politically volatile? The answer, according to our interviewees, is that you don’t. The talent pool is increasingly looking toward the private sector, where the pay is higher and the political interference is, at least, predictable.
3. Safety Signals and Regulatory Risk
Without the institutional memory provided by veteran staff, the risk of "regulatory capture" increases. When junior or less experienced staff are tasked with reviewing complex data sets, the agency becomes more reliant on the information provided by the sponsors themselves, rather than engaging in the robust, adversarial interrogation that the FDA is known for.
4. Global Standing
The FDA is the "gold standard" for regulatory agencies worldwide. Its decisions influence global health policy. A weakened FDA does not just affect American patients; it ripples through the global supply chain, potentially leading to a decline in international safety standards for food and medicine.
Conclusion: The Road Ahead
As we concluded our trip through the quiet suburbs of D.C., the prevailing mood among the former officials was one of quiet resignation mixed with profound concern. They are not bitter in the traditional sense; they are exhausted. They gave their careers to a public institution they believed in, only to watch it be disassembled by an administration that viewed their expertise as an obstacle rather than a foundation.
The FDA will continue to exist. New officials will be hired, new guidance documents will be drafted, and the lights will stay on at the White Oak campus. But the agency that emerges from the shadow of the DOGE era will be a different creature entirely. Whether it can regain the trust of the scientific community and the American public remains the defining question of the next decade.
For now, the experts have spoken. They left because they felt they had no choice. And as they watch from the sidelines, they wait to see if the institution they helped build can withstand the weight of its own transformation.
